DIRS.INFO The most relevant business & tech news

☆ First Republic deal boosts our banks. Danaher gets a confidence vote. Here are our takes on the news
▼ + stars: | 2023-05-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

That deposit money will be repaid to the participating banks, which include Club holdings Wells Fargo (WFC) and Morgan Stanley (MS). Wells Fargo deposited $5 billion , while Morgan Stanley contributed $2.5 billion. The Club's take: Morgan Stanley and Wells Fargo are stocks worth buying here, Jim Cramer said during Monday's "Morning Meeting." One potential drag on Morgan Stanley shares is JPMorgan's wealth management operations are strengthened by its First Republic acquisition. A man walks past a First Republic bank in Manhattan on May 01, 2023 in New York City.

☆ Sales, spins and splits — what are the differences and why do they matter for investors like us?
▼ + stars: | 2023-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +20 min

Investors may get one share in the spun-out entity for every share of the parent company they owned. What's left of J & J will be focused on pharmaceuticals and medical technologies, which were responsible for over 84% of the company's total 2022 revenue of $94.94 billion. It underscores that once free of the parent company tethers a divested company can chart its own destiny. Those priorities may not have necessarily been wrong when considering J & J as the overall enterprise. We believe J & J and Danaher are poised to deliver two more examples.

The insurance company posted 84 cents in adjusted earnings per share and $1.11 billion in revenue. However, the company's $592.2 million quarterly revenue fell below the $593.9 million anticipated by Wall Street. Although the company's quarterly adjusted earnings and revenue topped analysts' expectations, investors may have been disappointed in its muted full-year outlook. Danaher's GAAP operating profit of $1.79 billion fell below analysts' estimates of $2.12 billion, according to FactSet. General Motors — Shares fell 3.3% after the automaker lowered its guidance for net income attributable to stockholders in 2023.

☆ Club meeting recap: Stocks fall, Emerson upgrade, Danaher readthrough
▼ + stars: | 2023-04-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Stocks fall on earnings Emerson upgrade Danaher readthrough 1. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Wall Street on Tuesday upgraded two underperforming Club stocks — Emerson Electric (EMR) and Danaher (DHR) — to the equivalent of buy ratings. Historically, the iPhone's expensive price tag has hindered its ability to gain meaningful market share in the Indian smartphone market. We're confident Apple is gaining traction with Indian consumers , one reason why we continue to see Apple is a long-term investment. The company's two-pronged strategy of growing both its manufacturing- and consumer market share in India should prove fruitful in the coming years. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ We're adding to our position in this robust medical technology player
▼ + stars: | 2023-02-28 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

We are buying 15 shares of Danaher (DHR) at roughly $248.34 apiece. Following Tuesday's trade, Jim Cramer's Charitable Trust will own 495 shares of DHR, increasing its weighting in the portfolio to about 4.76% from 4.62%. Despite the company's strong fourth-quarter earnings beat in January, shares of Danaher are down about 11% since late January. DHR 1Y mountain Danaher (DHR) one-year performance. (Jim Cramer's Charitable Trust is long DHR.

☆ Coterra, Danaher and TJX Companies are in the news. Here's our take on the headlines
▼ + stars: | 2023-02-06 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

A trio of Club stocks — Coterra Energy (CTRA), Danaher (DHR) and TJX Companies (TJX) — are in the news Monday. The multiweek slide in natural gas prices is at the heart of Raymond James' downgrade because Coterra's revenue is split roughly 50-50 between natural gas and oil. @NG.1 5Y mountain Natural Gas prices over 5 years The Club's take: The decline in natural gas prices is undoubtedly going to affect the amount of cash Coterra generates and then returns to shareholders via its fixed-plus-variable dividend strategy and buybacks. We're not heading for the exits on Coterra despite the decline in natural gas prices. A photo of a natural gas flare burning near an oil pump jack at the New Harmony Oil Field in the U.S. on June 19, 2022.

☆ Danaher interested in buying life sciences firm Catalent, Bloomberg reports
▼ + stars: | 2023-02-04 | by ( ) www.reuters.com time to read: 1 min

Feb 4 (Reuters) - Medical equipment maker Danaher Corp (DHR.N) has expressed interest in taking over contract drugmaker Catalent Inc (CTLT.N), Bloomberg News reported on Saturday, citing people familiar with the matter. Danaher's approach to Catalent values it at a significant premium, the report said, adding that unclear how Catalent will proceed or whether it is receptive to a takeover offer. Both Danaher and Catalent did not immediately respond to a Reuters request for comment on the report. Danaher, which currently has a market capitalization of about $197 billion, bought privately-held biotech company Aldevron in an all-cash deal for about $9.6 billion in June 2021. Reporting by Juby Babu in Bengaluru Editing by Marguerita ChoyOur Standards: The Thomson Reuters Trust Principles.

☆ Danaher's stock drop looks like a buying opportunity after it reported a solid quarter
▼ + stars: | 2023-01-24 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

When excluding the impact of declining Covid testing sales — but keeping in revenue from products that support vaccines and therapeutics — Danaher's base business saw core growth of 7.5%. Guidance Management expects overall core revenue growth to be down mid-single-digits on a percentage for the first quarter. For the full year 2023, management expects overall core revenue growth to be down mid-single-digits. Previously, only revenues related to Covid testing were excluded. On the call, management pointed to roughly 10% core revenue growth in both North America and Europe.

☆ 2 of our stocks get nice pops. Here's the news and what we think
▼ + stars: | 2023-01-10 | by ( Zev Fima | ) www.cnbc.com time to read: +6 min

DHR 1Y mountain Danaher's 1 year stock performance Danaher is set to present at the JPMorgan Healthcare Conference on Tuesday afternoon. Now, management sees core sales growth up in the high single-digit range. In addition to the core revenue growth revision, management is now factoring in no growth coming from Covid-related testing. STZ 1Y mountain Constellation Brands 1-year stock performance;. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Credit Suisse downgrades Danaher as Covid vaccine demand dwindles
▼ + stars: | 2023-01-05 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

Credit Suisse is shifting its perspective on shares of Danaher as the company's bioprocess business comes under pressure. Analyst Dan Leonard downgraded the medical stock to neutral from outperform, citing exposure to bioprocessing inventory reductions that could threaten Danaher's growth. "Danaher has reduced its near-term growth expectations for its Bioprocess business (~25% of 2022e sales, ex COVID testing) as COVID vaccine demand has fallen and customers reduce inventory," he wrote in a note to clients Thursday. He trimmed his price target to $300 from $315 a share, with sales and earnings per shares expectations through 2025 coming in below Wall Street's expectations. The fresh target implies a near 13% jump for the stock after it shed more than 19% in 2022.

☆ Jim Cramer's Investing Club meeting Thursday: Avoid expensive stocks
▼ + stars: | 2023-01-05 | by ( Krystal Hur | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Avoid expensive stocks Stocks continued their drop on Thursday after the December ADP private payrolls report indicated the labor market remains strong. Still a buyer of Ford Ford Motor (F) said Thursday that it sold more than 75,000 F-series pickups in December, a 20% increase compared to last year. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ How we're thinking about our Club stock exposure to China following Covid protests
▼ + stars: | 2022-11-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Global stocks slumped Monday on growing concerns about intensifying protests across China over the communist government's strict Covid policies. Apple (AAPL) — Revenue from China : 17.7% (China is the iPhone maker's second-largest market, lagging just the U.S. at 37.5% of sales.) Disney (DIS) — Revenue from China: 4.8% Devon Energy (DVN) — Revenue from China: 0% Estee Lauder (EL) — Revenue from China: 29.7% (China is the cosmetic giant's largest sales market, followed by the U.S. at 19.8%, per FactSet.) Ford Motor (F) — Revenue from China: 4.6% Alphabet (GOOGL) — Revenue from China: 3.8% Halliburton (HAL) — Revenue from China: 1.6% Honeywell International (HON) — Revenue from China: 4.2% Humana (HUM) — Revenue from China: 0% Johnson & Johnson (JNJ) — Revenue from China: 3.1% Eli Lilly (LLY) — Revenue from China: 5.7% Linde (LIN) — Revenue from China: 8.1% Meta Platforms (META): Revenue from China: 2.6% Morgan Stanley (MS) — Revenue from China: 2.6% Microsoft (MSFT) — Revenue from China: 12.4% Nvidia (NVDA) — Revenue from China: 25.8% — keep in mind: Nvidia's revenue is not attributed to the country in which the consumer buys a product that contains one of the company's semiconductors. Procter & Gamble (PG) — Revenue from China: 13.7% (China is P & G's second-largest sales market, with the U.S. accounting for 45.5% of revenue).

☆ Jim Cramer says to buy shares of Danaher on the dip
▼ + stars: | 2022-10-21 | by ( Krystal Hur | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Friday advised investors to add Danaher to their shopping lists for next week after it reported third-quarter results. "You're now getting a chance to buy one of the best-run companies in the world at a big discount. Cramer said that this was a mistake, especially when considering that Danaher is an "arms dealer" of the pharma and biotech industry. And while investors might be worried about the decrease in business from the Covid market, the company is refocusing its spending on the much larger non-Covid space, Cramer said. Non-Covid bioprocessing sales grew well over 20%, and the company raised its expected full-year core sales growth forecast to the high-single-digit range.

☆ Cramer says the market got it wrong on Danaher's third quarter results
▼ + stars: | 2022-10-21 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer says the market got it wrong on Danaher's third quarter resultsCramer explained why investors shouldn't have sold off shares of Danaher after the company reported earnings this week.

☆ Danaher shares slide after knockout quarter. Here's why it's a buying opportunity
▼ + stars: | 2022-10-20 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

That trend is expected to continue and result in high-single-digit core revenue growth for the bioprocessing business for the full year. Driving the gains was 30% core revenue growth at Cepheid as the businesses respiratory testing revenue of about $875 million exceeded management's expectations of roughly $325 million. Guidance Management expects overall core revenue growth to be flat to down low-single-digits for the fourth quarter. For the full year 2022, management continues to forecast base business core revenue growth in the high-single-digit percent range. That's better than the 5.9% full-year core revenue growth expected on the Street.

☆ 2 takeaways from our daily meeting: Semiconductors, Danaher's earnings beat
▼ + stars: | 2022-10-20 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Sticking with our semiconductor strategy Semiconductor stocks climbed Thursday on the back of earnings beats from International Business Machines Corp. (IBM) and Lam Research (LRCX), with the broader market also rallying. Regardless, we don't regret our decision to trim our semiconductor stocks earlier this month. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ We're using this rally to make a few trades in the portfolio: one sale, two buys
▼ + stars: | 2022-10-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

We're buying 20 shares of Danaher (DHR) at roughly $263.99 and 40 shares of Estee Lauder (EL) at roughly $217.05. Estee Lauder We are taking some of that MRVL cash to add to our newest position Estee Lauder . When the pandemic hit and department stores temporarily closed their doors, Estee Lauder pivoted quickly and built direct-to-consumer channels like e-commerce. This shift has allowed Estee Lauder to recapture some lost market share and improve its operating margin outlook. Over the last three years, Estee Lauder has expanded its operating margins by 220 basis points.

☆ Analysts name the top 'high conviction' stocks for playing the market turbulence
▼ + stars: | 2022-09-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

CNBC Pro combed through top Wall Street research to find analysts' top "high conviction" ideas. With a Street high price target of $278, the stock is one of DA Davidson's top "high conviction" small cap ideas. DaVita The kidney and dialysis care provider was recently upgraded to a buy rating from neutral by investment firm UBS. UBS has a Street high price target of $117 per share, which implies a nearly 38% gain from the stock's current level. While a period of consolidation is possible, we have high conviction that CRWD is a unique investment vehicle as the modern security cloud, with exceptional long-term value creation potential."

☆ Danaher's decision to spin off its water business is a win-win for long-term investors
▼ + stars: | 2022-09-15 | by ( Zev Fima | ) www.cnbc.com time to read: +5 min

Danaher 's (DHR) announcement this week that it will spin off its growing water business is a big win for shareholders — including us at the Club. In both cases, after an initial growth hit due to the divestitures, we saw a notable sales growth acceleration once these slower growth business were on their own. More good news: Danaher's management team said 2022 core revenue growth is expected to be above the prior guidance range thanks higher-than-anticipated respiratory testing revenue at Cepheid. Base business core revenue growth is still expected to be up in the high-single-digit range. Whereas, they think EAS has a longer-term core revenue growth profile in the mid-single-digit range.

While the economy and the stock market are not the same, the companies that the stocks represent very much operate in and rely on the real economy. The thing to be mindful of here is that it's not just about strictly buying at lower levels 100% of the time. Building a position is something of an art form and the combination of your cost basis and recent buying activity are what should dictate your subsequent purchase activity. We believe Danaher's stock will go higher over time, allowing us to perhaps strategically book profits down the road. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Search resuls for: "Danaher's"

22 mentions found